NEOGENOMICS INC reported results for the period ended 2026 with revenue of $201.66M, net income of $2.24M and diluted EPS of $0.02, versus $181.33M, a net loss of ($45.09M) and diluted EPS of ($0.35) in the prior-year period.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$201.66M$181.33M11.2% | Net income²$2.24M($45.09M)105% | Diluted EPS³$0.02($0.35)105.7% |
¹ Reported as “Net Revenue”. ² Reported as “Net Income (Loss)”. ³ Reported as “Net Income (Loss) Per Share”.
Business Highlights
- Revenue growth of 11.2% year‑over‑year was driven by higher test volumes and unit price initiatives.
- Continued expansion in community oncology and hospital channels with targeted sales force growth.
- Rising adoption of PanTracer, PanTracer LBx, RaDaR MRD assays and Neo Comprehensive NGS panels supported product momentum.
- Operational improvements included better gross margins and faster turnaround times supported by investments in automation, digital pathology and platform upgrades.
- Increased R&D spending to advance MRD, whole genome and next‑generation assays while scaling commercialization efforts.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.